Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 1, 2004European Journal of Immunology

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

View Full Paper
Ask AI
Bookmark
Share

Authors

FGFrançois GhiringhelliUniversité Claude Bernard Lyon 1NLNicolas LarmonierUniversité de BordeauxESE. SchmittUniversidade Estadual do Oeste do Paraná

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ghiringhelli et al. (2004) studied this question.

synapsesocial.com/papers/6a0b6840bb648f6c2ac30ac7https://doi.org/10.1002/eji.200324181
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Induction of antigen-specific T cell anergy: An early event in the course of tumor progression1998 · 702 citations
  2. 2T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.1980 · 371 citations
  3. 3Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.1995 · 5,601 citations
  4. 4CD25 Is a Marker for CD4+ Thymocytes That Prevent Autoimmune Diabetes in Rats, But Peripheral T Cells with This Function Are Found in Both CD25+ and CD25− Subpopulations2000 · 312 citations
  5. 5Identification and Functional Characterization of Human Cd4+Cd25+ T Cells with Regulatory Properties Isolated from Peripheral Blood2001 · 1,258 citations